14.43
0.02 (0.14%)
| Penutupan Terdahulu | 14.41 |
| Buka | 14.42 |
| Jumlah Dagangan | 1,435,990 |
| Purata Dagangan (3B) | 6,969,405 |
| Modal Pasaran | 4,531,030,016 |
| Harga / Pendapatan (P/E Ke hadapan) | 30.49 |
| Harga / Jualan (P/S) | 7.05 |
| Harga / Buku (P/B) | 16.59 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| Margin Keuntungan | -5.41% |
| Margin Operasi (TTM) | -6.35% |
| EPS Cair (TTM) | -0.090 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 13.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 229.11% |
| Nisbah Semasa (MRQ) | 3.34 |
| Aliran Tunai Operasi (OCF TTM) | 3.56 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 29.27 M |
| Pulangan Atas Aset (ROA TTM) | 3.95% |
| Pulangan Atas Ekuiti (ROE TTM) | -18.12% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Amicus Therapeutics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -5.0 |
| Osilator Teknikal | 0.0 |
| Purata | -0.25 |
|
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.72% |
| % Dimiliki oleh Institusi | 103.25% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |